Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2474人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866425, encodeId=a1f8186642559, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, objectType=article, longId=292261, objectId=67d0292261ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d0292261ff, replyNumber=0, likeNumber=72, createdTime=2022-04-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d0292261ff, moduleTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d0292261ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866206, encodeId=65d6186620622, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, objectType=article, longId=216406, objectId=13bc21640686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bc21640686, replyNumber=0, likeNumber=77, createdTime=2022-02-11, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bc21640686, moduleTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bc21640686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866354, encodeId=91ae186635475, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, objectType=article, longId=220501, objectId=7da92205016e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7da92205016e, replyNumber=0, likeNumber=51, createdTime=2022-09-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7da92205016e, moduleTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7da92205016e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866327, encodeId=1097186632e21, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：乳腺癌化疗后大脑认知功能减退的罪魁祸首, objectType=article, longId=219560, objectId=db8421956062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db8421956062, replyNumber=0, likeNumber=112, createdTime=2021-12-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db8421956062, moduleTitle=J Clin Oncol：乳腺癌化疗后大脑认知功能减退的罪魁祸首, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db8421956062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866355, encodeId=ff43186635520, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：外科医师对微创手术的熟练程度影响早期宫颈癌患者的预后：来自851例患者的回顾性研究, objectType=article, longId=220515, objectId=13e4220515f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13e4220515f8, replyNumber=0, likeNumber=66, createdTime=2022-11-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13e4220515f8, moduleTitle=Front Oncol：外科医师对微创手术的熟练程度影响早期宫颈癌患者的预后：来自851例患者的回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13e4220515f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866500, encodeId=c45c18665009b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, objectType=article, longId=295365, objectId=755a295365ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=755a295365ca, replyNumber=0, likeNumber=83, createdTime=2022-09-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=755a295365ca, moduleTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=755a295365ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866145, encodeId=ec9118661456c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！, objectType=article, longId=213845, objectId=5610213845c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5610213845c0, replyNumber=0, likeNumber=64, createdTime=2022-04-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5610213845c0, moduleTitle=J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5610213845c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866402, encodeId=e47c186640279, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：早期乳腺癌的内分泌治疗中加用帕博西利的效果, objectType=article, longId=221755, objectId=19c6221e5512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19c6221e5512, replyNumber=0, likeNumber=64, createdTime=2022-09-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19c6221e5512, moduleTitle=J Clin Oncol：早期乳腺癌的内分泌治疗中加用帕博西利的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19c6221e5512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866585, encodeId=b120186658584, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, objectType=article, longId=723824, objectId=cc6fe23824f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc6fe23824f3, replyNumber=0, likeNumber=66, createdTime=2023-01-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc6fe23824f3, moduleTitle=Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc6fe23824f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866329, encodeId=3343186632959, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=0, createdTime=2021-11-14, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866552, encodeId=a096186655252, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, objectType=article, longId=301132, objectId=c2d23011325d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d23011325d, replyNumber=0, likeNumber=58, createdTime=2022-03-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d23011325d, moduleTitle=Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d23011325d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866469, encodeId=ab13186646929, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, objectType=article, longId=294587, objectId=24a229458ebf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24a229458ebf, replyNumber=0, likeNumber=100, createdTime=2022-10-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24a229458ebf, moduleTitle=Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24a229458ebf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866138, encodeId=0199186613811, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, objectType=article, longId=213616, objectId=dc3421361646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc3421361646, replyNumber=0, likeNumber=0, createdTime=2022-05-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3421361646, moduleTitle=J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc3421361646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866332, encodeId=ae241866332e3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=219747, objectId=c80a219e4706, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c80a219e4706, replyNumber=0, likeNumber=92, createdTime=2022-06-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c80a219e4706, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c80a219e4706)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866132, encodeId=693118661329d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, objectType=article, longId=213322, objectId=b9b021332249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b021332249, replyNumber=0, likeNumber=78, createdTime=2021-07-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b021332249, moduleTitle=Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9b021332249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866489, encodeId=e46d186648923, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, objectType=article, longId=295133, objectId=e466295133ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e466295133ba, replyNumber=0, likeNumber=92, createdTime=2022-12-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e466295133ba, moduleTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e466295133ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866193, encodeId=84df18661936d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, objectType=article, longId=215670, objectId=64082156e056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64082156e056, replyNumber=0, likeNumber=55, createdTime=2022-05-13, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64082156e056, moduleTitle=J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64082156e056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866526, encodeId=6d7d186652639, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌, objectType=article, longId=299552, objectId=e37a29955264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37a29955264, replyNumber=0, likeNumber=94, createdTime=2022-11-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37a29955264, moduleTitle=J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37a29955264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866084, encodeId=e4391866084e2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle= FRONT ONCOL投稿经验分享, objectType=article, longId=211352, objectId=768d21135283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768d21135283, replyNumber=0, likeNumber=13, createdTime=2021-12-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768d21135283, moduleTitle= FRONT ONCOL投稿经验分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=768d21135283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866243, encodeId=f871186624313, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤, objectType=article, longId=217541, objectId=850e21e541b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850e21e541b6, replyNumber=0, likeNumber=84, createdTime=2022-07-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850e21e541b6, moduleTitle=JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850e21e541b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY

2022-04-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果

2022-02-11

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响

2022-09-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：乳腺癌化疗后大脑认知功能减退的罪魁祸首

2021-12-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：外科医师对微创手术的熟练程度影响早期宫颈癌患者的预后：来自851例患者的回顾性研究

2022-11-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效

2022-09-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol ：我国不限瘤种PD-L1快要来了，晚期实体瘤患者精准治疗新选择！

2022-04-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：早期乳腺癌的内分泌治疗中加用帕博西利的效果

2022-09-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：转移性肾透明细胞癌的三种一线治疗方案的疗效和安全性

2023-01-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2021-11-14

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：BRAF突变与错配修复基因缺失(MMR-D)/高微卫星不稳定性(MSI-H)转移性结直肠癌(mCRC)较差预后相关

2022-03-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：真实世界数据探索EGFR 18外显子突变NSCLC患者的治疗策略和预后

2022-10-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：多纳非尼(Donafenib)与索拉非尼(Sorafenib)在不可切除或转移性肝癌一线治疗中的对比:一项随机、开放、平行对照的II-III期试验

2022-05-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2022-06-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：普拉替尼有望用于治疗RET融合阳性的非小细胞肺癌（ARROW试验）

2021-07-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性

2022-12-09

docwu2019 (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：吉西他滨联合顺铂较氟尿嘧啶联合顺铂改善复发性或转移性鼻咽癌患者的预后: III期研究GEM20110714最终OS分析

2022-05-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Selumetinib联合放射性碘治疗高风险的分化型甲状腺癌

2022-11-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

FRONT ONCOL投稿经验分享

2021-12-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：卡非佐米+来那度胺+地塞米松继以来那度胺维持可有效预防高危冒烟型骨髓瘤进展成多发性骨髓瘤

2022-07-01

科室
- - 订阅+
  - 更多科室
工具
服务